{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 52,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "kpi_overview",
  "function": "quantify_opportunity",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a matrix structure to segment the market by disease stage and molecular profile, overlaying clinical trial names (e.g., AEGEAN, FLAURA) as product markers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/28",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.22,
        "x": 0.75,
        "y": 0.22
      },
      "kind": "callout",
      "text": "Leading the future of lung cancer treatment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e554d5a-b7e2-4e95-b5f2-d0cb0442d438",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Est epi (G7) = estimated epidemiology across G7... Collaboration partners: Daiichi Sankyo, Compugen.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15bc2193-c132-4291-9191-bd8e754e9224",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.22,
        "x": 0.75,
        "y": 0.35
      },
      "kind": "list",
      "text": "Tagrisso established TKI backbone in EGFRm; Imfinzi leading IO in unresectable; Advancing best-in-class ADCs; Delivering next-wave bispecifics; Developing novel combinations; Investing in new technologies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd5ba0ac-e6cc-44a6-92b5-c69b9128a4a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.7,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "table",
      "text": "Matrix of patient segments (resectable, unresectable, metastatic) vs tumor drivers (IO sensitive, EGFRm, etc.) with drug/trial names.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4277b192-342a-4c52-ae8c-968be12c065b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32508700-db5a-4151-8bd6-1807c05474d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "AstraZeneca in Lung Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5dfa04d5-a975-42c7-b1af-912384a9f707",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "fa9d09be-2c00-4fd5-911b-bc9c9617990f",
      "evidence": "Segmentation of lung cancer patients by stage and molecular driver",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 52,
      "from": 26,
      "beatId": "a55635e0-23e3-4936-80d1-f995ad7f0061",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck concludes with a roadmap for future growth, potential new options for patients, and a summary of key messages",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}